AUGX vs. AMWL, MPLN, DCTH, SYRS, ANVS, MOLN, ELMD, SCLX, BPTS, and ZURA
Should you be buying Augmedix stock or one of its competitors? The main competitors of Augmedix include American Well (AMWL), MultiPlan (MPLN), Delcath Systems (DCTH), Syros Pharmaceuticals (SYRS), Annovis Bio (ANVS), Molecular Partners (MOLN), Electromed (ELMD), Scilex (SCLX), Biophytis (BPTS), and Zura Bio (ZURA). These companies are all part of the "medical" sector.
Augmedix (NASDAQ:AUGX) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking.
Augmedix currently has a consensus target price of $5.17, suggesting a potential upside of 80.02%. American Well has a consensus target price of $1.00, suggesting a potential upside of 83.96%. Given American Well's higher possible upside, analysts clearly believe American Well is more favorable than Augmedix.
Augmedix has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, American Well has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
In the previous week, American Well had 2 more articles in the media than Augmedix. MarketBeat recorded 5 mentions for American Well and 3 mentions for Augmedix. American Well's average media sentiment score of 0.34 beat Augmedix's score of 0.03 indicating that American Well is being referred to more favorably in the news media.
Augmedix has higher earnings, but lower revenue than American Well. Augmedix is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
87.1% of Augmedix shares are owned by institutional investors. Comparatively, 56.1% of American Well shares are owned by institutional investors. 11.0% of Augmedix shares are owned by insiders. Comparatively, 12.9% of American Well shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
American Well received 29 more outperform votes than Augmedix when rated by MarketBeat users. However, 60.00% of users gave Augmedix an outperform vote while only 48.48% of users gave American Well an outperform vote.
Augmedix has a net margin of -42.74% compared to American Well's net margin of -260.63%. American Well's return on equity of -40.19% beat Augmedix's return on equity.
Summary
American Well beats Augmedix on 10 of the 18 factors compared between the two stocks.
Get Augmedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Augmedix Competitors List
Related Companies and Tools
